LA JOLLA, Calif. -- Scientists at The Scripps Research Institute have given new superpowers to a lifesaving antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections for years to come.
The researchers, led by Dale Boger, co-chair of the Scripps Research department of chemistry, discovered a way to structurally modify vancomycin to make an already-powerful version of the antibiotic even more potent.
“Doctors could use this modified form of vancomycin without fear of resistance emerging,” said Boger, whose team announced the finding Monday in the journal Proceedings of the National Academy of Sciences.
The original form of vancomycin is an ideal starting place for developing better antibiotics. The antibiotic has been prescribed by doctors for 60 years, and bacteria are only now developing resistance to it. This suggests bacteria already have a hard time overcoming vancomycin’s original “mechanism of action,” which works by disrupting how bacteria form cell walls.
Boger called vancomycin “magical” for its proven strength against infections, and previous studies by Boger and his colleagues at Scripps had shown that it is possible to add two modifications to vancomycin to make it even more potent. “With these modifications, you need less of the drug to have the same effect,” Boger said.
The new study shows that scientists can make a third modification -- which interferes with a bacterium’s cell wall in a new way -- with promising results. Combined with the previous modifications, this alteration gives vancomycin a 1,000-fold increase in activity, meaning doctors would need to use less of the antibiotic to fight infection.
The discovery makes this version of vancomycin the first antibiotic to have three independent mechanisms of action.
“This increases the durability of this antibiotic,” Boger said. “Organisms just can’t simultaneously work to find a way around three independent mechanisms of action. Even if they found a solution to one of those, the organisms would still be killed by the other two.”
Tested against Enterococci bacteria, the new version of vancomycin killed both vancomycin-resistant Enterococci and the original forms of Enterococci.
The next step in this research is to design a way to synthesize the modified vancomycin using fewer steps in the lab, as the current method takes 30 steps. But Boger calls this the “easy part” of the project, compared with the challenge of designing the molecule in the first place.
Even if the process isn’t streamlined, Boger believes the new vancomycin’s lifesaving powers make its production valuable.
“Antibiotics are total cures for bacterial infections,” Boger said. “Making this molecule is important, even by the current approach, if the failure of antibiotics continues.”
In addition to Boger, authors of the study, “Peripheral modifications of vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics,” included first author Akinori Okano and Nicholas A. Isley, both of Scripps Research.
The study was supported by the National Institutes of Health (grants F32 GM114948 and CA041101).
The Scripps Research Institute is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. For more information, see the website here.